Cargando…

Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil

INTRODUCTION: Severe uncontrolled chronic rhinosinusitis with nasal polyps has a negative impact on an individual’s quality of life. Therefore, new biologics have emerged for use in specific phenotypes of chronic rhinosinusitis, changing the paradigms of its treatment. OBJECTIVE: To review the curre...

Descripción completa

Detalles Bibliográficos
Autores principales: Anselmo-Lima, Wilma T., Tamashiro, Edwin, Romano, Fabrizio R., Miyake, Marcel M., Roithmann, Renato, Kosugi, Eduardo M., Nakanishi, Márcio, Fornazieri, Marco A., Bezerra, Thiago F.P., Mello, João F., Lessa, Marcus M., Voegels, Richard L., Piltcher, Otávio B., Sakano, Eulalia, Valera, Fabiana C.P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422446/
https://www.ncbi.nlm.nih.gov/pubmed/33867274
http://dx.doi.org/10.1016/j.bjorl.2021.03.003
_version_ 1784777813702737920
author Anselmo-Lima, Wilma T.
Tamashiro, Edwin
Romano, Fabrizio R.
Miyake, Marcel M.
Roithmann, Renato
Kosugi, Eduardo M.
Nakanishi, Márcio
Fornazieri, Marco A.
Bezerra, Thiago F.P.
Mello, João F.
Lessa, Marcus M.
Voegels, Richard L.
Piltcher, Otávio B.
Sakano, Eulalia
Valera, Fabiana C.P.
author_facet Anselmo-Lima, Wilma T.
Tamashiro, Edwin
Romano, Fabrizio R.
Miyake, Marcel M.
Roithmann, Renato
Kosugi, Eduardo M.
Nakanishi, Márcio
Fornazieri, Marco A.
Bezerra, Thiago F.P.
Mello, João F.
Lessa, Marcus M.
Voegels, Richard L.
Piltcher, Otávio B.
Sakano, Eulalia
Valera, Fabiana C.P.
author_sort Anselmo-Lima, Wilma T.
collection PubMed
description INTRODUCTION: Severe uncontrolled chronic rhinosinusitis with nasal polyps has a negative impact on an individual’s quality of life. Therefore, new biologics have emerged for use in specific phenotypes of chronic rhinosinusitis, changing the paradigms of its treatment. OBJECTIVE: To review the current status of biologic treatment indications in chronic rhinosinusitis. METHODS: The Brazilian Academy of Rhinology brought together different specialists to suggest a course of action, considering its particularities and aspects related to the national reality. RESULTS: Of particular interest for decision making will be the identification of subgroups of patients refractory to pre-existing treatment options and the construction of a strategy that improves their quality of life, with the best cost-benefit ratio. CONCLUSION: The use of biologics is a valid option for treatment in more severe cases. This strategy must be better understood and improved in the future, with more studies and greater clinical experience.
format Online
Article
Text
id pubmed-9422446
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-94224462022-08-31 Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil Anselmo-Lima, Wilma T. Tamashiro, Edwin Romano, Fabrizio R. Miyake, Marcel M. Roithmann, Renato Kosugi, Eduardo M. Nakanishi, Márcio Fornazieri, Marco A. Bezerra, Thiago F.P. Mello, João F. Lessa, Marcus M. Voegels, Richard L. Piltcher, Otávio B. Sakano, Eulalia Valera, Fabiana C.P. Braz J Otorhinolaryngol Review Article INTRODUCTION: Severe uncontrolled chronic rhinosinusitis with nasal polyps has a negative impact on an individual’s quality of life. Therefore, new biologics have emerged for use in specific phenotypes of chronic rhinosinusitis, changing the paradigms of its treatment. OBJECTIVE: To review the current status of biologic treatment indications in chronic rhinosinusitis. METHODS: The Brazilian Academy of Rhinology brought together different specialists to suggest a course of action, considering its particularities and aspects related to the national reality. RESULTS: Of particular interest for decision making will be the identification of subgroups of patients refractory to pre-existing treatment options and the construction of a strategy that improves their quality of life, with the best cost-benefit ratio. CONCLUSION: The use of biologics is a valid option for treatment in more severe cases. This strategy must be better understood and improved in the future, with more studies and greater clinical experience. Elsevier 2021-04-03 /pmc/articles/PMC9422446/ /pubmed/33867274 http://dx.doi.org/10.1016/j.bjorl.2021.03.003 Text en © 2021 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier Editora Ltda. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review Article
Anselmo-Lima, Wilma T.
Tamashiro, Edwin
Romano, Fabrizio R.
Miyake, Marcel M.
Roithmann, Renato
Kosugi, Eduardo M.
Nakanishi, Márcio
Fornazieri, Marco A.
Bezerra, Thiago F.P.
Mello, João F.
Lessa, Marcus M.
Voegels, Richard L.
Piltcher, Otávio B.
Sakano, Eulalia
Valera, Fabiana C.P.
Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil
title Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil
title_full Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil
title_fullStr Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil
title_full_unstemmed Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil
title_short Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil
title_sort guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (crswnp) in brazil
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422446/
https://www.ncbi.nlm.nih.gov/pubmed/33867274
http://dx.doi.org/10.1016/j.bjorl.2021.03.003
work_keys_str_mv AT anselmolimawilmat guidelinefortheuseofimmunobiologicalsinchronicrhinosinusitiswithnasalpolypscrswnpinbrazil
AT tamashiroedwin guidelinefortheuseofimmunobiologicalsinchronicrhinosinusitiswithnasalpolypscrswnpinbrazil
AT romanofabrizior guidelinefortheuseofimmunobiologicalsinchronicrhinosinusitiswithnasalpolypscrswnpinbrazil
AT miyakemarcelm guidelinefortheuseofimmunobiologicalsinchronicrhinosinusitiswithnasalpolypscrswnpinbrazil
AT roithmannrenato guidelinefortheuseofimmunobiologicalsinchronicrhinosinusitiswithnasalpolypscrswnpinbrazil
AT kosugieduardom guidelinefortheuseofimmunobiologicalsinchronicrhinosinusitiswithnasalpolypscrswnpinbrazil
AT nakanishimarcio guidelinefortheuseofimmunobiologicalsinchronicrhinosinusitiswithnasalpolypscrswnpinbrazil
AT fornazierimarcoa guidelinefortheuseofimmunobiologicalsinchronicrhinosinusitiswithnasalpolypscrswnpinbrazil
AT bezerrathiagofp guidelinefortheuseofimmunobiologicalsinchronicrhinosinusitiswithnasalpolypscrswnpinbrazil
AT mellojoaof guidelinefortheuseofimmunobiologicalsinchronicrhinosinusitiswithnasalpolypscrswnpinbrazil
AT lessamarcusm guidelinefortheuseofimmunobiologicalsinchronicrhinosinusitiswithnasalpolypscrswnpinbrazil
AT voegelsrichardl guidelinefortheuseofimmunobiologicalsinchronicrhinosinusitiswithnasalpolypscrswnpinbrazil
AT piltcherotaviob guidelinefortheuseofimmunobiologicalsinchronicrhinosinusitiswithnasalpolypscrswnpinbrazil
AT sakanoeulalia guidelinefortheuseofimmunobiologicalsinchronicrhinosinusitiswithnasalpolypscrswnpinbrazil
AT valerafabianacp guidelinefortheuseofimmunobiologicalsinchronicrhinosinusitiswithnasalpolypscrswnpinbrazil